相关实验视频

Updated: May 10, 2026

Using Chicken Embryo as a Powerful Tool in Assessment of Developmental Cardiotoxicities
11:00

Using Chicken Embryo as a Powerful Tool in Assessment of Developmental Cardiotoxicities

Published on: March 21, 2021

4.1K

在医疗器械临床前安全评估中推进发育和生殖评估

Julie Juyoung Park1, Alan Hood2

  • 1US FDA, Center for Drug Evaluation and Research, Office of New Drugs, Office of Nonprescription Drugs, Silver Spring, MD, USA.

Regulatory toxicology and pharmacology : RTP
|May 21, 2025
PubMed
概括

一项新的研究探讨了使用计算模型来预测医疗器械化学品中的发育和生殖毒性 (DART). 结合特定的in silico模型显示为安全评估的第一步,可能减少动物试验.

关键词:
发展和生殖毒性毒性.发展性毒性 发展性毒性在的中.医疗器械 医疗器械是一种医疗器械.在临床前的临床前.生殖性毒性 生殖性毒性

更多相关视频

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.7K
Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis07:45

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

293

相关概念视频

In vitro Mutagenesis01:16

In vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Development of the Sexual Organs in the Embryo and Fetus01:15

Development of the Sexual Organs in the Embryo and Fetus

Development of the reproductive organs in an embryo starts from a bipotential state. This means the early embryo can develop either male or female reproductive organs. The formation of these organs begins with the growth of gonadal ridges that arise from the intermediate mesoderm during the fifth week of development.
Near the gonadal ridges, two duct systems are present: the mesonephric ducts (Wolffian ducts) and paramesonephric ducts (Müllerian ducts). These ducts form the basis for the male...
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...